Australia markets open in 8 minutes

Atea Pharmaceuticals, Inc. (AVIR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.69+0.44 (+5.33%)
At close: 04:00PM EST
8.69 0.00 (0.00%)
After hours: 05:39PM EST
Full screen
Trade prices are not sourced from all markets
Previous close8.25
Open8.31
Bid8.21 x 2200
Ask8.69 x 3000
Day's range8.02 - 8.73
52-week range7.37 - 94.17
Volume1,503,431
Avg. volume5,068,526
Market cap722.162M
Beta (5Y monthly)N/A
PE ratio (TTM)27.85
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

    BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 3:05 p.m. ET. A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of

  • GlobeNewswire

    Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche

    Atea to lead global clinical trial development of AT-527 and regain ex-US commercial rightsBOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the strategic collaboration pursuant to which it was jointly developing AT-527 for the treatment of COVID-19 with Roche will be terminating. Upon termination, the rights and licenses granted by Atea to Roche under the strategic collaboration will be

  • GlobeNewswire

    Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results

    Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased Dose, with Plan to Accelerate Completion of Enrollment Infectious Virus Data Demonstrate AT-527’s Rapid and Potent Antiviral Activity Against COVID-19 in Phase 2 MOONSONG Overall Patient Population Cohort B and High-Risk Patient Subgroup New In Vitro Results Demonstrate AT-511 (Free Base of AT-527) Potent Activity Against COVID-19 Variants of Concern and/or of Interest, Including Delta